Maintenance fees coming due
Regeneron Pharmaceuticals, Inc.
275 maintenance fees come due in the 12 months from Nov 18, 2026, the next on Dec 2, 2026. Unpaid by Jun 2, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 9,043,996 | Genetically Modified Major Histocompatibility Complex Animals In force Fee due Dec 2, 2026 Lapses if unpaid Jun 2, 2027 · High confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 2, 2026 | Jun 2, 2027 | High confidence | |
| US 10,306,874 | Non-Human Animals Having a Humanized Lymphocyte-Activation Gene 3 In force Fee due Dec 4, 2026 Lapses if unpaid Jun 4, 2027 · High confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 4, 2026 | Jun 4, 2027 | High confidence | |
| US 11,666,040 | Humanized Non-Human Animals with Restricted Immunoglobulin Heavy Chain Loci In force Fee due Dec 6, 2026 Lapses if unpaid Jun 7, 2027 · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 6, 2026 | Jun 7, 2027 | Medium confidence | |
| US 11,666,658 | Rifamycin Analogs and Antibody-Drug Conjugates Thereof In force Fee due Dec 6, 2026 Lapses if unpaid Jun 7, 2027 · High confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 6, 2026 | Jun 7, 2027 | High confidence | |
| US 11,667,701 | Anti-PfRH5 Antibodies and Antigen-Binding Fragments Thereof In force Fee due Dec 6, 2026 Lapses if unpaid Jun 7, 2027 · High confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 6, 2026 | Jun 7, 2027 | High confidence | |
| US 10,314,296 | Genetically Modified Major Histocompatibility Complex Mice In force Fee due Dec 11, 2026 Lapses if unpaid Jun 11, 2027 · High confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 11, 2026 | Jun 11, 2027 | High confidence | |
| US 10,314,904 | Methods for Enhancing Efficacy of a Vaccine by Administering an IL-4R Antagonist In force Fee due Dec 11, 2026 Lapses if unpaid Jun 11, 2027 · High confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 11, 2026 | Jun 11, 2027 | High confidence | |
| US 10,316,105 | ANTI-TIE2 Antibodies and Uses Thereof In force Fee due Dec 11, 2026 Lapses if unpaid Jun 11, 2027 · High confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 11, 2026 | Jun 11, 2027 | High confidence | |
| US 11,673,930 | Novel IL10 Agonists and Methods of Use Thereof In force Fee due Dec 13, 2026 Lapses if unpaid Jun 14, 2027 · High confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 13, 2026 | Jun 14, 2027 | High confidence | |
| US 11,673,967 | Stabilized Formulations Containing ANTI-PCSK9 Antibodies In force Fee due Dec 13, 2026 Lapses if unpaid Jun 14, 2027 · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Dec 13, 2026 | Jun 14, 2027 | Medium confidence | |
| 265 more maintenance fees coming due in the 12 months from Nov 18, 2026 · Pro | |||||||
10 of 275 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.